Biomind Labs Inc. (CVE:BMND.NE) | Finanzwire

Basculer en Français

10820	Companies
234662	Keywords
163523	Articles
125584	Press releases

Home
Companies
Biomind Labs Inc.

BRIEF

published on 08/06/2026 at 22:20, 5 days 9 hours ago

Biomind Labs to List on Canadian Securities Exchange

Investment Opportunities Canadian Securities Exchange Biopharmaceutical Delisting Biomind Labs
PRESS RELEASE

published on 08/06/2026 at 22:15, 5 days 9 hours ago

Biomind Labs Announces Listing on the Canadian Securities Exchange and the Delisting From the Cboe Canada
Biomind Labs Inc. to list Common Shares on the Canadian Securities Exchange (CSE) under symbol 'BMND' starting August 11, 2026, delisting from Cboe Canada on August 10, 2026. No action needed from shareholders. Company focused on CNS therapeutics

Common Shares Canadian Securities Exchange Delisting Biomind Labs Inc. CNS Therapeutics
BRIEF

published on 04/20/2026 at 14:35, 3 months 21 days ago

Biomind Labs Welcomes U.S. Executive Order on Psychedelic Research

FDA Mental Health Biomind Labs Executive Order Psychedelic Research
PRESS RELEASE

published on 04/20/2026 at 14:30, 3 months 21 days ago

Biomind Labs Applauds Landmark Executive Order Accelerating Psychedelic Research and Access in The United States
President Trump signs executive order to fast-track research and patient access to psychedelic therapies, aligning with Biomind's mission to transform neuropsychiatric care

Psychedelic Therapies Mental Health Neurodegenerative Disorders Biomind Labs Regulatory Acceleration
BRIEF

published on 01/27/2026 at 22:20, 6 months 15 days ago

Biomind Labs Secures CAD $2.52 Million Through Private Placement

Private Placement Toronto Neuroscience Biopharmaceuticals Biomind Labs
PRESS RELEASE

published on 01/27/2026 at 22:15, 6 months 15 days ago

Biomind Labs Announces CAD $2.52 Million Private Placement Financing
Biomind Labs Inc. launches a non-brokered private placement of up to 28,000,000 units at $0.09 per unit, aiming to raise up to C$2,520,000 for advancing clinical programs and working capital

Private Placement Clinical Development Neuroscience Biomind Labs Inc. Pharmaceutical Drugs
BRIEF

published on 12/03/2025 at 14:35, 8 months 8 days ago

Biomind Labs Advances BMND08 with New Nano-Formulation

Intellectual Property Biomind Labs BMND08 FDA Pathway Nano-formulation
PRESS RELEASE

published on 12/03/2025 at 14:30, 8 months 8 days ago

Biomind Labs Accelerates FDA Pathway for 5-MEO-DMT Candidate BMND08 with Proprietary Nano-Formulation as Patent Observations Are Successfully Withstood
Biomind Labs advances BMND08 into FDA-directed activities with newly engineered nano-formulation drug-delivery platform, strengthening patent position

FDA Patent Biomind Labs BMND08 Nano-formulation
BRIEF

published on 11/25/2025 at 23:25, 8 months 16 days ago

Biomind Labs Announces Revocation of Cease Trade Order

Cease Trade Order Financial Challenges Going Concern Biomind Labs Disclosures Filed
PRESS RELEASE

published on 11/25/2025 at 23:20, 8 months 16 days ago

Biomind Labs Announces Revocation of Cease Trade Order
Biomind Labs Inc. announces the Ontario Securities Commission revokes cease trade order, allowing the filing of Continuous Disclosure Documents. The Company to hold AGSM before February 25, 2026

Cease Trade Order Ontario Securities Commission AGSM Biomind Labs Inc. Continuous Disclosure Documents

Accesswire

Published on 08/12/2026 at 00:00, 7 hours 21 minutes ago

Organto Foods Reports Record Second Quarter 2026 Financial Results
Published on 08/11/2026 at 23:40, 7 hours 41 minutes ago

RJK Explorations Ltd. Announces Private Placement for Gross Proceeds of up to $100,000
Published on 08/11/2026 at 23:15, 8 hours 6 minutes ago

Fermi and Hillcore Energy Capital Announce 2.6 Gigawatt Power Strategic Alliance for Project Matador
Published on 08/11/2026 at 23:00, 8 hours 21 minutes ago

Prospectiva Resources Ltd. Completes Qualifying Transaction
Published on 08/11/2026 at 22:55, 8 hours 26 minutes ago

NV Gold Announces Non-Brokered Private Placement

View all ACCESSWIRE

EQS Group

Published on 08/12/2026 at 07:10, 10 minutes ago

Deutsche Konsum Real Estate AG publishes quarterly statement for the first nine months of the 2025/2026 financial year
Published on 08/12/2026 at 07:00, 20 minutes ago

MindMaze Therapeutics Appoints Prof. John W. Krakauer as Strategic Advisor
Published on 08/12/2026 at 07:00, 20 minutes ago

SCHOTT Pharma with strong third quarter and on track for planned growth
Published on 08/12/2026 at 07:00, 20 minutes ago

TUI delivered resilient Q3 underlying EBIT of €234.6m (at CC), demonstrating the strength of its business despite geopolitical headwinds and one-offs, FY26 guidance reaffirmed
Published on 08/12/2026 at 07:00, 20 minutes ago

E.ON remains on track and continues to invest in the energy transition

Les Echos

Published on 08/10/2026 at 18:00, 1 day 13 hours ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 17:45, 1 day 13 hours ago

Weekly share buyback
Published on 08/10/2026 at 11:53, 1 day 19 hours ago

GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
Published on 08/10/2026 at 11:36, 1 day 19 hours ago

GUILLEMOT CORPORATION| Weekly report share buyback from August 3 to August 7 2026
Published on 08/10/2026 at 09:22, 1 day 21 hours ago

Number of shares and voting rights - July 2026 (In French only)

View all LES ECHOS COMFI WIRE